Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for MARAVIROC
- A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by GVHD Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV (PLWH)
- Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study
- Safety and Efficacy of Maraviroc in Post-stroke Cognitive Impairment
- The Role of Home Packs of HIV PEPSE in High Risk Individuals
- The Canadian Maraviroc RCT To Augment Rehabilitation Outcomes After Stroke
- Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)
- Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults
- Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
- Maraviroc in Patients With Moderate and Severe COVID-19
- Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients
- Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.
- Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
- ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence
- Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio
- Maraviroc to Augment Rehabilitation Outcomes After Stroke
- Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)
- Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV
- Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients
- Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure
- Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients
- Maraviroc Efficacy for Hepatitis C
- Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation
- Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
- Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
- THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC
- Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)
- Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication
- A Open-label, Drug-Drug Interaction With Maraviroc (DDI)
- Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection
- Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women
- Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults
- Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
- Maraviroc as GVHD Prophylaxis in Transplant Recipients
- Maraviroc and NeuroAIDS Pathogenesis
- Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes
- A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants
- Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites
- Switch to Maraviroc + Integrase Inhibitor
- A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc
- Rosuvastatin to Decrease Residual Immune Activation in HIV Infection
- Switching Undetectables to Selzentry
- Phase II Maraviroc for GVHD Prevention
- An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc
- Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women
- CCR5-blockade in Metastatic Colorectal Cancer
- First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers
- A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study
- MARCH Renal Substudy
- MARCH Central Nervous System Substudy
- The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers
- Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects
- A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™
- MARCH Vascular Endothelium Substudy
- Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)
- Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
- A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)
- Safety Study of Maraviroc's Effect on Human Osteoclasts
- Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy
- Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
- Maraviroc Abacavir STudy - Effect on Endothelial Recovery
- Maraviroc Switch Collaborative Study
- Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia
- Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa
- Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)
- Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring
- The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study
- Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
- Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
- A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
- Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients
- Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects
- Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)
- Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia
- A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium
- Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3
- Hydroxychloroquine for Discordant CD4 Responders on Highly Active Antiretroviral Therapy (HAART)
- R5 Integrase Study in HIV-1 Naive Patients
- PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing Regimen
- Effects of Intensive cART During Acute/Early HIV Infection
- Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects
- Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects
- Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)
- Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)
- Effect Of Maraviroc On The Pharmacokinetics Of Digoxin
- Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens
- Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)
- Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients
- Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1
- A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
- Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients
- Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels
- The Maraviroc Central Nervous System (CNS) Study
- The St. Marys and The Mater Switch Study
- Pilot Assessment of Lopinavir/Ritonavir and Maraviroc
- IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults
- Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
- Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects
- Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
- Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration
- CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery
- Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects
- Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
- Maraviroc Immune Recovery Study
- A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy
- Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)
- Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc
- Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection
- Effect of Maraviroc on Endothelial Function in HIV-Infected Patients
- A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients
- Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers
- Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine
- A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
- Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1
- An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
- A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects
- Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients
- Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal Tissue
- Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers
- An Interaction Study to Assess Drug Levels in Healthy Adult Subjects
- Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
- Maraviroc Compassionate Use
- Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
- Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression
- Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
- Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc
- A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects
- Prospective Observational Epidemiologic Study of Maraviroc's Safety
- Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
- Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
- Optimizing Treatment for Treatment-Experienced, HIV-Infected People
- Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)
- Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay
- Multicenter, Safety Study Of Maraviroc
- Maraviroc in Rheumatoid Arthritis
- Expanded Access Program for Maraviroc At Multiple Centers
- Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects
- Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
- Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects
- Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
Clinical trials list
click for details